1229 / 1674
Overview
•
The natural history of ”low risk” breast cancer
•
Caution about fractionation
–
Fractionation theories
–
Experience from Norway and Sweden
•
Preliminary results
–
Problems reported from the RAPID trial
–
Problems reported from the ELIOT trial
–
Problems reported from the TARGIT trial
•
Non-scientific reasons for use of APBI